Published in J Clin Invest on July 15, 1996
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest (2006) 2.50
Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol (2007) 2.25
Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med (1999) 2.23
Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med (2005) 1.85
Generation of C5a by phagocytic cells. Am J Pathol (2002) 1.72
Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor. Am J Pathol (2000) 1.46
Novel chemokine responsiveness and mobilization of neutrophils during sepsis. Am J Pathol (2004) 1.42
Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am J Pathol (2003) 1.42
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol (2012) 1.34
NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement. Am J Pathol (1998) 1.23
Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol (2008) 1.22
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit Care (2009) 1.20
Cross-talk between TLR4 and FcgammaReceptorIII (CD16) pathways. PLoS Pathog (2009) 1.20
Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS One (2009) 1.16
Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci U S A (2006) 1.14
C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol (2008) 1.13
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension (2010) 1.12
Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med (1998) 1.08
Complement activation promotes muscle inflammation during modified muscle use. Am J Pathol (2000) 1.07
Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J (2009) 1.07
Molecular mechanisms of inflammation and tissue injury after major trauma--is complement the "bad guy"? J Biomed Sci (2011) 1.04
MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I. J Immunol (2012) 1.03
The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol (2000) 1.02
Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. Am J Pathol (1999) 0.98
Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin Exp Immunol (2004) 0.98
Targeted disruption of the gene encoding the murine small subunit of carboxypeptidase N (CPN1) causes susceptibility to C5a anaphylatoxin-mediated shock. J Immunol (2009) 0.98
Mechanisms of enhanced lung injury during sepsis. Am J Pathol (1999) 0.97
Rous-Whipple Award Lecture. Role of complement in lung inflammatory injury. Am J Pathol (1996) 0.97
Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats. Shock (2013) 0.97
Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol (1999) 0.96
Activator protein-1 activation in acute lung injury. Am J Pathol (2002) 0.95
Anti-inflammatory effects of mutant forms of secretory leukocyte protease inhibitor. Am J Pathol (2000) 0.95
Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury. Inflammation (1999) 0.90
Zonulin as prehaptoglobin2 regulates lung permeability and activates the complement system. Am J Physiol Lung Cell Mol Physiol (2013) 0.89
Anti-KC autoantibody:KC complexes cause severe lung inflammation in mice via IgG receptors. Am J Respir Cell Mol Biol (2007) 0.86
Mediators of microvascular injury in dermal burn wounds. Inflammation (1998) 0.86
Role of chemotactic factors in neutrophil activation after thermal injury in rats. Inflammation (1999) 0.86
Differing patterns of P-selectin expression in lung injury. Am J Pathol (1998) 0.86
Neutrophil chemotactic activity and C5a following systemic activation of complement in rats. Inflammation (1997) 0.84
Sepsis and ARDS: The Dark Side of Histones. Mediators Inflamm (2015) 0.83
Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem (2013) 0.83
The role of the complement system in acute kidney injury. Semin Nephrol (2013) 0.83
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis (2005) 0.81
Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps. Expert Opin Ther Targets (2014) 0.81
Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin. FASEB J (2015) 0.78
Endotoxin-induced lung inflammation is independent of the complement membrane attack complex. Infect Immun (2000) 0.76
C5L2, the Second C5a Anaphylatoxin Receptor, Suppresses LPS-Induced Acute Lung Injury. Am J Respir Cell Mol Biol (2016) 0.75
New Insights into Molecular Mechanisms of Immune Complex-Induced Injury in Lung. Front Immunol (2016) 0.75
Inadequate cytoplasmatic calcium signals in alveolar macrophages after cardiac surgery. Inflamm Res (2010) 0.75
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest (1989) 4.59
Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest (1977) 4.08
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem (1989) 2.20
The role of complement in inflammation and phagocytosis. Immunol Today (1991) 2.04
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest (1986) 1.71
Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol (1979) 1.69
Role of complement activation in a model of adult respiratory distress syndrome. J Clin Invest (1980) 1.55
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation. Am J Pathol (1980) 1.46
Role of beta 1, beta 2 integrins and ICAM-1 in lung injury after deposition of IgG and IgA immune complexes. J Immunol (1993) 1.44
Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol (1989) 1.44
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest (1995) 1.40
Production of acute pulmonary injury by leukocytes and activated complement. Surgery (1980) 1.40
Mediators of lung injury in mice following systemic activation of complement. Am J Pathol (1985) 1.28
The pulmonary response of C5 sufficient and deficient mice to immune complexes. Am Rev Respir Dis (1981) 1.26
Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. J Immunol (1992) 1.26
Monocyte chemoattractant protein 1 in a rat model of pulmonary granulomatosis. Lab Invest (1992) 1.22
Role of leukocyte adhesion molecules in complement-induced lung injury. J Immunol (1993) 1.14
Platelet-serotonin release by C3a and C5a: two independent pathways of activation. J Immunol (1981) 1.13
Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol (1987) 1.08
Complement activation during cardiopulmonary bypass. Anaesthesia (1980) 1.06
Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am J Pathol (1987) 1.06
Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res (1989) 0.99
Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol (1994) 0.93
Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol (1993) 0.91
Complement-induced vascular leukostasis. Its role in tissue injury. Arch Pathol Lab Med (1980) 0.91
Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation. Circ Res (1983) 0.91
Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci (1994) 0.83
Role of complement in inflammation and bacterial killing. Curr Stud Hematol Blood Transfus (1992) 0.81
Increase in salicylic Acid at the onset of systemic acquired resistance in cucumber. Science (1990) 10.47
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc Natl Acad Sci U S A (1978) 6.28
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science (1989) 5.08
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates. Exp Cell Res (1979) 4.61
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Antibody to prekeratin. Decoration of tonofilament like arrays in various cells of epithelial character. Exp Cell Res (1978) 4.01
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol (1981) 3.37
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med (2001) 3.01
HeLa cells contain intermediate-sized filaments of the prekeratin type. Exp Cell Res (1979) 2.98
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A (1981) 2.94
Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol (1976) 2.90
Oxygen and carbon dioxide fluxes from barley shoots depend on nitrate assimilation. Plant Physiol (1989) 2.72
Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates. J Biol Chem (1972) 2.72
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med (1981) 2.63
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
Functional analysis of alternatively spliced tyrosinase gene transcripts. EMBO J (1988) 2.60
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Synthesis and degradation of barley nitrate reductase. Plant Physiol (1983) 2.55
Intermediate-sized filaments of the prekeratin type in myoepithelial cells. J Cell Biol (1980) 2.54
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Root respiration associated with ammonium and nitrate absorption and assimilation by barley. Plant Physiol (1992) 2.51
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies. Proc Natl Acad Sci U S A (1989) 2.43
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Inheritance of nitrate reductase activity in Zea mays L. Proc Natl Acad Sci U S A (1969) 2.38
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation (1995) 2.36
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem (1978) 2.32
Differentiation-related patterns of expression of proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb Symp Quant Biol (1982) 2.32
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
Biochemical and immunological identification of cytokeratin proteins present in hepatocytes of mammalian liver tissue. Exp Cell Res (1981) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Formation of cytoskeletal elements during mouse embryogenesis. Intermediate filaments of the cytokeratin type and desmosomes in preimplantation embryos. Differentiation (1980) 2.17
Re-evaluation of the RBE of 29 kV x-rays (mammography x-rays) relative to 220 kV x-rays using neoplastic transformation of human CGL1-hybrid cells. Radiat Environ Biophys (2003) 2.16
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Intermediate filament proteins in nonfilamentous structures: transient disintegration and inclusion of subunit proteins in granular aggregates. Cell (1982) 2.13
Reduced Accumulation of ABA during Water Stress in a Molybdenum Cofactor Mutant of Barley. Plant Physiol (1989) 2.13
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
Regional anaesthesia and cancer metastases: the implication of local anaesthetics. Acta Anaesthesiol Scand (2013) 2.11
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08
Structure and function of the anaphylatoxins. Springer Semin Immunopathol (1984) 2.07
Intermediate-sized filaments of human endothelial cells. J Cell Biol (1979) 2.06
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
Identification and characterization of epithelial cells in mammalian tissues by immunofluorescence microscopy using antibodies to prekeratin. Differentiation (1979) 2.01
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol (2000) 1.97
Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med (2000) 1.96
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93